Collectively, the above findings indicate that patients in the low risk-group are more likely to benefit from immunotherapy, and the CD8+ T cell-related risk score could act as a potential biomarker to distinguish ovarian cancer patients who may benefit from immunotherapy. Here, CD8A is linked to ovarian cancer.